Antibodies selective for pathological tau dimers and prefibrillar pathological tau oligomers and their uses in treatment, diagnosis and monitoring of tauopathies
Antibodies selective for pathological tau dimers and/or prefibrillar pathological tau oligomers, immunogenic peptides and epitopes of these antibodies, hydridomas producing these antibodies, uses of these antibodies, immunogenic peptides and epitopes in preparation of pharmaceutical compositions for the treatment of tauopathies, and uses of these antibodies, immunogenic peptides, epitopes and pharmaceutical compositions in the treatment of tauopathies are described. Also described are uses of these antibodies, immunogenic peptides, epitopes in diagnosis and monitoring of tauopathies.
1. A tau oligomeric complex-1 (TOC-1) monoclonal antibody comprising the heavy variable region of SEQ ID NO:7.
2. The antibody of claim 1 , which is an IgG antibody.
3. The antibody of claim 1 , wherein the antibody selectively recognizes prefibrillar Tau aggregates comprising at least two tau proteins cross-linked to each other, either directly or through a linker at one or more cysteine residues.
4. The antibody of claim 1 , wherein the antibody comprises the light variable region of SEQ ID NO: 8.
5. The antibody of claim 1 , wherein the antibody selectively recognizes a conformation induced by a cross-linked Tau dimer, wherein the cross-linked Tau dimer comprises at least two tau proteins cross-linked in vitro to each other, either directly or through a linker, at one or more cysteine residues.
6. An antibody comprising a variable region of the heavy chain which is the same as the heavy variable region of SEQ ID NO:7.
7. The antibody of claim 6 , the epitope of which comprises a minimum of two Tau monomers.
8. The antibody of claim 6 , whose epitope lies within ninety amino acids of a MTBR of hTau40.
9. The antibody of claim 8 , whose epitope lies within a region of hTau40 selected from the group consisting of Gly 155 -Gln 244 , Leu 376 -Ser 421 , Cys 291 -Arg 349 , or a fragment of any of the foregoing.
10. The antibody of claim 9 , wherein the epitope lies within Gly 155 -Gln 244 or a fragment thereof.
11. The antibody of claim 6 , wherein the antibody selectively recognizes prefibrillar Tau aggregates comprising at least two tau proteins cross-linked to each other, either directly or through a linker at one or more cysteine residues.
12. The antibody of claim 6 , wherein the antibody selectively recognizes a conformation induced by a cross-linked Tau dimer, wherein the cross-linked Tau dimer comprises at least two tau proteins cross-linked in-vitro to each other, either directly or through a linker, at one or more cysteine residues.
13. The antibody of claim 6 , which is an IgG antibody.
14. The antibody of any one of claim 1 or 6 , which requires for binding a conformation comprising:
at least two cross-linked Tau molecules, and
a region of hTau40 selected from the group consisting of Gly 155 -Gln 244 , Leu 376 -Ser 421 , Cys 291 -Arg 349 , or a fragment of any of the foregoing.
15. A method of treating a tauopathy in a mammal, comprising administering to a mammal in need of therapy for a tauopathy an antibody according to claim 1 or an antibody according to claim 6 .
16. The antibody of claim 1 or 6 , which does not selectively recognize monomeric Tau.
17. The antibody of claim 1 or 6 , which does not selectively react with α-synuclein.
18. The antibody of claim 1 or 6 , which does not selectively react with Aβ in the unaggregated, oligomeric or filamentous states.
19. The antibody of claim 1 or 6 , which is an IgM antibody.